Process Research and Translation, Tengion, Inc., 3929 Westpoint Blvd., Suite G, Winston-Salem, NC 27103, USA.
Trends Biotechnol. 2013 Sep;31(9):505-14. doi: 10.1016/j.tibtech.2013.05.007. Epub 2013 Aug 6.
Methodologies for the rigorous and quantitative evaluation of biological activity or potency are an essential aspect of the developmental pathway for all biologic product candidates. Such assays typically leverage key mechanistic pathways demonstrated to mediate observed therapeutic outcomes. Tissue engineered/regenerative medicine (TE/RM) therapeutics include cell based therapies as well as engineered tissues and neo-organs for which clarity regarding the mechanism or mechanisms of action may not be forthcoming. Here, we discuss how strategies for the development of potency assays for TE/RM product candidates may harness potential mechanisms of action or other therapeutically relevant bioactivity along with cell number and viability. As the pipeline for TE/RM product candidates expands through 2014 and beyond, the establishment of a defined framework for potency assays will facilitate successful translational outcomes.
对于所有生物制品候选物,严格和定量评估生物学活性或效价的方法是其开发途径的一个重要方面。此类检测通常利用关键的机制途径来证明与观察到的治疗结果相关。组织工程/再生医学(TE/RM)治疗学包括基于细胞的治疗方法以及工程组织和新器官,对于这些方法,作用机制或机制可能尚不清楚。在这里,我们讨论了如何为 TE/RM 产品候选物开发效价检测方法,以利用潜在的作用机制或其他治疗相关的生物活性,以及细胞数量和活力。随着 2014 年及以后 TE/RM 产品候选物的不断发展,建立一个明确的效价检测框架将有助于实现成功的转化结果。